Tags

Type your tag names separated by a space and hit enter

A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Cancer Epidemiol Biomarkers Prev. 2006 Feb; 15(2):217-27.CE

Abstract

BACKGROUND

Matriptase, a type II transmembrane serine protease is involved in angiogenesis, degradation of extracellular matrix, and in the progression of some epithelial cancers. Here, we establish the clinical significance of matriptase and its inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1), during the progression of human prostate cancer (CaP).

METHODS

The expression patterns of matriptase and HAI-1 were determined in primary cultures of normal human prostate epithelial (NHPE) cells, human CaP cells LNCaP, DU-145, CWR22Rnu1, and PC-3, and in tissue samples of 172 patients with normal prostate, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and adenocarcinoma of different tumor grades.

RESULTS

The protein and mRNA levels of matriptase were significantly higher in all carcinoma cells as compared with NHPE cells. Conversely, all CaP cells exhibited a reduced expression of HAI-1 as compared with NHPE cells. A progressive increase in the protein levels of matriptase was observed with increasing tumor grade in CaP specimens as compared with normal and BPH tissue specimens. Tissue samples of normal prostate exhibited a high constitutive protein level of HAI-1 compared with BPH and low-grade cancer with a progressive loss with increasing tumor grade.

CONCLUSION

The increased expression of matriptase and loss of HAI-1 may be an important event during the progression of CaP in humans. We suggest that the ratio of these two gene products may serve as a promising biomarker for CaP progression and a potential marker for establishing the efficacy of therapeutic and chemopreventive interventions.

Authors+Show Affiliations

Saleem M
Department of Dermatology, Laboratory of Medicine, University of Wisconsin, 1300 University Avenue, Medical Sciences Center, B-25, Madison, Wisconsin 53706, USA.
Adhami VM
No affiliation info available
Zhong W
No affiliation info available
Longley BJ
No affiliation info available
Lin CY
No affiliation info available
Dickson RB
No affiliation info available
Reagan-Shaw S
No affiliation info available
Jarrard DF
No affiliation info available
Mukhtar H
No affiliation info available

MeSH

AdenocarcinomaBiomarkers, TumorDisease ProgressionEpithelial CellsHumansMaleMembrane GlycoproteinsNeoplasm StagingProstatic NeoplasmsProteinase Inhibitory Proteins, SecretoryRNA, MessengerSerine EndopeptidasesTumor Cells, Cultured

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16492908

Citation

Saleem, Mohammad, et al. "A Novel Biomarker for Staging Human Prostate Adenocarcinoma: Overexpression of Matriptase With Concomitant Loss of Its Inhibitor, Hepatocyte Growth Factor Activator Inhibitor-1." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 15, no. 2, 2006, pp. 217-27.
Saleem M, Adhami VM, Zhong W, et al. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev. 2006;15(2):217-27.
Saleem, M., Adhami, V. M., Zhong, W., Longley, B. J., Lin, C. Y., Dickson, R. B., Reagan-Shaw, S., Jarrard, D. F., & Mukhtar, H. (2006). A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 15(2), 217-27.
Saleem M, et al. A Novel Biomarker for Staging Human Prostate Adenocarcinoma: Overexpression of Matriptase With Concomitant Loss of Its Inhibitor, Hepatocyte Growth Factor Activator Inhibitor-1. Cancer Epidemiol Biomarkers Prev. 2006;15(2):217-27. PubMed PMID: 16492908.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. AU - Saleem,Mohammad, AU - Adhami,Vaqar Mustafa, AU - Zhong,Weixiong, AU - Longley,B Jack, AU - Lin,Chen-Yong, AU - Dickson,Robert B, AU - Reagan-Shaw,Shannon, AU - Jarrard,David F, AU - Mukhtar,Hasan, PY - 2006/2/24/pubmed PY - 2006/6/16/medline PY - 2006/2/24/entrez SP - 217 EP - 27 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol Biomarkers Prev VL - 15 IS - 2 N2 - BACKGROUND: Matriptase, a type II transmembrane serine protease is involved in angiogenesis, degradation of extracellular matrix, and in the progression of some epithelial cancers. Here, we establish the clinical significance of matriptase and its inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1), during the progression of human prostate cancer (CaP). METHODS: The expression patterns of matriptase and HAI-1 were determined in primary cultures of normal human prostate epithelial (NHPE) cells, human CaP cells LNCaP, DU-145, CWR22Rnu1, and PC-3, and in tissue samples of 172 patients with normal prostate, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and adenocarcinoma of different tumor grades. RESULTS: The protein and mRNA levels of matriptase were significantly higher in all carcinoma cells as compared with NHPE cells. Conversely, all CaP cells exhibited a reduced expression of HAI-1 as compared with NHPE cells. A progressive increase in the protein levels of matriptase was observed with increasing tumor grade in CaP specimens as compared with normal and BPH tissue specimens. Tissue samples of normal prostate exhibited a high constitutive protein level of HAI-1 compared with BPH and low-grade cancer with a progressive loss with increasing tumor grade. CONCLUSION: The increased expression of matriptase and loss of HAI-1 may be an important event during the progression of CaP in humans. We suggest that the ratio of these two gene products may serve as a promising biomarker for CaP progression and a potential marker for establishing the efficacy of therapeutic and chemopreventive interventions. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/16492908/A_novel_biomarker_for_staging_human_prostate_adenocarcinoma:_overexpression_of_matriptase_with_concomitant_loss_of_its_inhibitor_hepatocyte_growth_factor_activator_inhibitor_1_ DB - PRIME DP - Unbound Medicine ER -